Daniel J. Rosenthal | White & Case LLP International Law Firm, Global Law Practice
Daniel Rosenthal
Daniel Rosenthal

Daniel J. Rosenthal

Associate, Washington, DC

T +1 202 729 2512

E [email protected]

Overview

Daniel Rosenthal is an associate in the Firm’s Global Antitrust/Competition Practice. Daniel’s primary areas of focus include government merger investigations, antitrust counselling, and advising clients on global cross-border transactions with multiple merger clearance requirements. Daniel has experience representing clients in all phases of merger clearance before the Federal Trade Commission and Department of Justice, as well as before federal courts in litigated challenges by the government. He has assisted clients in a broad range of industries, including healthcare, pharmaceuticals, biotechnology, manufacturing, petroleum, transportation, automobile components, semiconductors, software, hardware, chemicals, energy, entertainment, and retail sales. Daniel also regularly counsels clients on issues relating to the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) as well as international merger notification requirements.

Bars and Courts

  • US District Court for the District of Columbia
  • District of Columbia Bar
  • Massachusetts State Bar
  • New York State Bar

Education

  • JD, University of Virginia School of Law
  • BA, Emory University

Languages

  • English

Experience

Vertex Pharmaceuticals, Inc., in its acquisition of cystic fibrosis drug, CTP-656, from Concert Pharmaceuticals, Inc., for up to US$250 million.

Anthem, Inc., in its attempted US$54.2 billion acquisition of Cigna Corporation.

Shenzhen Hepalink Pharmaceuticals' acquisition of Scientific Protein Laboratories for US$337.5 million.

Ciner Group in its US$480 million cross border strategic acquisition of a controlling interest in OCI Resources LP, a global producer of natural soda ash, from OCI Company Ltd., a Korean publicly listed company.

Iconix Brand Group, Inc. in the US$345 million sale of its entertainment division to DHX Media Ltd. Iconix’s entertainment division included an 80 percent controlling interest in the Peanuts branded business, including content featuring Snoopy, Charlie Brown, Lucy and other well-known characters, and 100 percent of the Strawberry Shortcake business and its related characters.

Fortis Inc., Canada's largest publicly-owned distribution utility, in its US$11.3 billion acquisition of ITC Holdings Corp., an electric transmission company operating in the Great Lakes and Great Plains regions.

Dynegy Inc., the third-largest independent power producer in the United States, in its US$2.8 billion acquisition of ownership interests in certain Midwest generation assets from Duke Energy Corp, almost doubling Dynegy's generating capacity less than a year after emerging from bankruptcy protection.

Regal Beloit Corporation, a leading global manufacturer of electric motors, mechanical and electrical motion controls and power generation products, in its US$1.44 billion acquisition of the Power Transmissions Solutions business of Emerson Electric Co. 

NeuroDerm Ltd., an Israel-based, Nasdaq-listed clinical stage pharmaceutical company developing drug-device combinations for central nervous system disorders, in its US$1.1 billion sale to Mitsubishi Tanabe Pharma Corporation.

Hess Corporation in the US$850 million disposition of its US East Coast and St. Lucia terminal network to Buckeye Partners.

Publications

  • Merger Control in the United States, Merger Control Comparative Guide (2nd Edition), The Legal 500 and The In-House Lawyer, (with Anna Kertesz)
  • Future Antitrust Merger Enforcement in the United States, Taiwan: Cross-border Opportunities Amid Global Change, June 14, 2017, (with George L. Paul)